Lawmakers seek clarity from GAO on remdesivir

House Oversight Committee Chair Carolyn Maloney (D-NY) and Sen. Debbie Stabenow (D-MI) want the Government Accountability Office (GAO) to find out how much the federal government has invested in the research and development of Gilead Science’s drug remdesivir, which is being used to treat patients with COVID-19. In an interview, Stabenow suggested that Gilead could curb supply hurdles by licensing remdesivir to generic suppliers, or that the federal government could invoke the Defense Production Act to mandate more supplies. Maloney and Stabenow’s letter to the GAO is available here.